The QualityStocks Daily Friday, March 15th, 2019

Today's Top 3 StockMarketWatch

StockMarketWatch (SLNO) +98.52%

NetworkNewsWire (RNWR) +58.82%

QualityStocks (VMHG) +55.00%

The QualityStocks Daily Stock List

Rhino Resource Partners LP (RHNO)

Zacks, MarketWatch, Mining Connection, GlobeNewswire, Annual Reports, TopPennyStockMovers, Marketbeat, Simply Wall St, 4-Traders, Dividend Channel, Wall Street Mover, and PCG Advisory reported earlier on Rhino Resource Partners LP (RHNO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Rhino Resource Partners LP is a diversified energy limited partnership. It concentrates on coal and energy related assets and activities. This includes energy infrastructure investments. Rhino is a diversified energy MLP (Master Limited Partnership). It produces coal in numerous basins in the U.S.  Rhino Resource Partners has its head office in Lexington, Kentucky.

The Company, through acquisitions and other coal lease transactions, has substantially increased its proven and probable coal reserves and non-reserve coal deposits. Furthermore, Rhino has successfully increased its coal production by way of internal development projects.

The Company produces metallurgical and steam coal in an array of basins across the U.S. as well as leases coal. Rhino’s strategy is to acquire coal reserves and properties with relatively long lives and that could undergo development with low risk at a reasonable cost.

Rhino produces steam coal used to produce electricity and metallurgical coal used in the steel-making process. In addition, the Company manages and leases coal properties and collects royalties from such management and leasing activities. Rhino also has oil and gas investments in the Cana Woodford region that provides added cash flows to its business.

In Central Appalachia, approximately 72 percent of its full-year 2019 thermal and met coal production has been contracted at increased prices in comparison to 2018. Rhino’s Pennyrile, Castle Valley and Hopedale operations are considerably sold out for 2019 at prices that are above the Company’s 2018 levels. Moreover, Rhino has executed long-term contracts with different utility customers for thermal coal for 2020 at Pennyrile and Castle Valley.

This week, Rhino Resource Partners announced its financial and operating results for the quarter ended December 31, 2018. For the quarter, the Partnership reported a Net Loss of $5.6 million and Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $6.3 million, versus a Net Loss of $18.7 million and Adjusted EBITDA of $6.7 million in Q4 of 2017.

Diluted Net Loss Per Common Unit was $0.49 for the quarter versus Diluted Net Loss Per Common Unit of $1.45 for Q4 of 2017. Total Revenues for the quarter were $64.7 million, with coal sales producing $63.9 million of the total, versus Total Revenues of $55.8 million and coal revenues of $55.4 million in the fourth quarter of 2017.

Rhino Resource Partners LP (RHNO), closed Friday's trading session at $1.20, down 20.00%, on 1,370 volume with 10 trades. The average volume for the last 3 months is 1,155 and the stock's 52-week low/high is $0.80/$2.50.

chart

Exicure, Inc. (XCUR)

Insider Monkey, BioPortfolio, OTC Markets, Street Insider, MarketWatch, Business Wire, Stockopedia, Nasdaq, Morningstar, YCharts, 4-Traders, Stockwatch, GuruFocus, Simply Wall St, Penny Stock Hub, Trading View, Last10k, Adis Insight, Investors Hangout, Wallet Investor, Open Insider, Insider Mole, The Street, Interactive Brokers, Seeking Alpha and InvestorsHub reported earlier on Exicure, Inc. (XCUR), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Exicure, Inc. is a clinical stage biotechnology company listed on the OTC Markets Group’s OTCQB. It is developing a new class of immunomodulatory and gene regulating drugs against validated targets. The Company’s lead programs focus on oncology, inflammatory diseases, and genetic disorders. Exicure is a pioneer in gene regulatory and immunotherapeutic drugs using spherical nucleic acid (SNA™) constructs. Exicure is headquartered in Chicago, Illinois.

The Company's intellectual property (IP) portfolio includes more than 140 pending patent applications and over 55 allowed or issued patents. These filings include a range of inventions. These include fundamental nanoparticle manufacturing breakthroughs and manifold application-specific improvements.

Regarding Partnering and Licensing, Exicure’s strategy is to maximize the potential of its Spherical Nucleic Acid (SNA) technology platform by way of in-house development, collaborations, and licensing. Additionally, the Company may form platform partnerships with pharmaceutical companies across numerous indications or within specific therapeutic areas.

Exicure’s proprietary 3-dimensional, Spherical Nucleic Acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a broad array of cells and tissues. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics - the safe and effective delivery into cells and tissues.

The Company is employing its SNA technology to mobilize the body's natural defense against cancer. Its lead immunotherapy compound, AST-008 (initially being investigated in selected solid and hematological tumors) is a toll-like receptor 9 agonist. The design of it is to use the SNA's beneficial properties to propel a robust anti-cancer immune response.

Exicure announced this past December top-line results from a Phase 1 clinical trial evaluating XCUR17 in patients with mild-to-moderate chronic plaque psoriasis. XCUR17 is an SNA drug targeted to mRNA encoding interleukin 17 receptor alpha, or IL-17RA. IL-17RA is a key protein that propagates inflammation. In preclinical studies, XCUR17 inhibited IL-17RA expression in human skin and in psoriatic mouse models.

In February, Exicure announced that it dosed the first patient in its multicenter, open-label, Phase 1b/2 study of AST-008 combined with pembrolizumab. Enrollment in the trial is open to patients with superficial injectable tumors in advanced or metastatic solid tumor conditions. These include Merkel cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma and melanoma. The primary goal of the Phase 1b dose escalation stage is to measure the safety and tolerability of the Company’s AST-008 drug alone and in combination with pembrolizumab, and to ascertain a dose for the Phase 2 stage of the study.

Exicure recently provided an update on corporate progress. Dr. David Giljohann, Exicure’s Chief Executive Officer, said, “We’re very proud of our achievements on each of our strategic priorities for 2018. We drove two programs through Phase 1 clinical trials while laying the foundation for expanding our pipeline in neurology, rare dermatology, ophthalmology and gastroenterology. We also strengthened the management of our company and our access to capital. In the coming year, we expect to execute and advance our ongoing clinical programs, while expanding into new therapeutic areas.”

Exicure, Inc. (XCUR), closed Friday's trading session at $2.4735, up 3.06%, on 81,519 volume with 63 trades. The average volume for the last 3 months is 30,870 and the stock's 52-week low/high is $2.00/$6.50.

chart

Patriot One Technologies, Inc. (PTOTF)

Investor Ideas, Small Cap Network, Profit Confidential, Zacks, Stockhouse, Barchart, MarketWatch, Seeking Alpha, Investors Hangout, OTC Markets, Trading View, 4-Traders, Morningstar, Market Screener, Wallet Investor, Investing Daily, GuruFocus, Dividend Investor, Insider Financial, InvestorsHub and Streetwise Reports reported earlier on Patriot One Technologies, Inc. (PTOTF), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, Patriot One Technologies, Inc. develops radar device and software solutions.  The Company and a research team at McMaster University in Hamilton, Ontario have come together to commercialize a system to detect concealed weapons utilizing novel radar technologies and custom software solutions. Patriot One Technologies is headquartered in Burlington, Ontario.

The Company has developed PATSCAN™. This is the next generation of its award-winning Patriot One Technologies™ NForce CMR1000 software and radar solution. PATSCAN™ is a first-of-its-kind Cognitive Microwave Radar (CMR) concealed weapons detection system as an effective tool to combat active shooter threats before they occur.

Patriot One is commercializing its PATSCAN™ CMR technology as an automated alert system, which can covertly screen moving individuals for on-body concealed weapons. PATSCAN™  can alert security of an active threat entering the site.

PATSCAN identifies threats by database comparison of known weapons profiles, and through detection of concealed irregular object mass. The Company’s patented Cognitive Microwave Radar (CMR) uses a network-wide ability to “learn” and adapt to new threats as “signature” patterns are identified. Pattern updates are transmitted network-wide. This provides an ever-growing signature library.

PATSCAN has completed all required testing. It now has certification by the European Telecommunications Standards Institute (ETSI). This makes PATSCAN saleable in 66 nations throughout Europe, the Middle East, and Asia.

This past January, Patriot One Technologies announced the closing of its acquisition of EhEye, Inc. of New Brunswick, Canada. EhEye is now a wholly-owned subsidiary of Patriot One and its video recognition software rebranded as PATSCAN VRS. In connection with and pursuant to the terms of the Transaction, Patriot One Technologies’ new video analytics team will be led by Dr. James Stewart, Ph.D.  Dr. Stewart now holds the role of Senior VP of Video Analytics for Patriot One.

Furthermore, in January, Patriot One Technologies announced it entered into a binding operating agreement regarding the formation of a new Joint Venture (JV) to commercialize a technology for the stand-off detection of explosives and other threats, including chemical and biological agents and also illicit narcotics, which has been branded as PATSCAN MCS (multi-chemical sensor). The JV is between Patriot One Technologies and Nano-Bio Detection Systems LLC. Nano-Bio is a Wyoming company that holds licensed technology from the University of Texas used for the detection of airborne molecules.

Patriot One Technologies, Inc. (PTOTF), closed Friday's trading session at $2.00, up 0.72%, on 221,082 volume with 254 trades. The average volume for the last 3 months is 185,598 and the stock's 52-week low/high is $0.926/$2.289.

chart

Ivanhoe Mines Ltd. (IVPAF)

Predict Wall Street, Market Screener, Junior Mining Network, The Street, Resource World, Wallet Investor, OTC Markets, Street Register, Stock News Union, Mining.com, Barchart, 4-Traders, MarketWatch, Northern Miner, Stockhouse, Insider Financial, Canadian Mining Report, YCharts and InvestorsHub reported earlier on Ivanhoe Mines Ltd. (IVPAF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Ivanhoe Mines Ltd. engages in the exploration, development, and recovery of minerals and precious metals located primarily in Africa. It is focusing on advancing its three main projects in Southern Africa. These include the development of new mines at the Kamoa-Kakula copper discovery in the Democratic Republic of Congo (DRC) and the Platreef platinum-palladium-nickel-copper-gold discovery in South Africa. Additionally, these include the extensive redevelopment and upgrading of the historic Kipushi zinc-copper-germanium-silver mine in the DRC. OTCQX-listed, Ivanhoe Mines is headquartered in Vancouver, British Columbia.

The Company explores for platinum, palladium, nickel, copper, gold, rhodium, zinc, germanium, and lead deposits. Ivanhoe Mines and China’s CITIC Metal Co., Ltd. signed a long-term strategic cooperation and investment agreement in June of 2018. The agreement will see CITIC Metal invest aprroximately C$723 million ($557 million) to help advance Ivanhoe’s three projects in Southern Africa. With this investment agreement, CITIC Metal acquired a 19.5 percent stake in Ivanhoe Mines by way of a private placement at a price of C$3.68 per share.

Ivanhoe Mines previously announced a new Mineral Resource estimate for the Kipushi Mine. The estimate increased zinc-rich Measured and Indicated Mineral Resources by 16 percent, from 10.2 million tonnes to 11.8 million tonnes. Furthermore, this new estimate increased Kipushi’s zinc grade from 34.89 percent to 35.34 percent. The mine’s copper-rich Measured and Indicated Resources have also increased by 40 percent from 1.6 million tonnes to 2.3 million tonnes, with a small increase in the copper grade from 4.01 percent to 4.03 percent.

A Pre-Feasibility Study for Phase 1 of the Kamoa-Kakula Project is also taking place. The expectation is that it will be completed by early 2019. The planned initial, six-million-tonne-per-annum (Mtpa) mine at Kakula is estimated to cost $1.2 billion.

On October 1, 2018, Ivanhoe Mines announced the Makoko Copper Discovery on its 100 percent-owned Western Foreland exploration licenses, near Kamoa-Kakula in the DRC. Makoko is Ivanhoe’s third major copper discovery in the DRC. Makoko shows geological characteristics identical to the tier-one Kamoa-Kakula Discoveries.

Recently, Ivanhoe Mines reported an unprecedented 22.3-meter intersection of 13.05% Copper in a shallow, flat-lying discovery at the Kamoa North Copper Exploration Area on the Kamoa-Kakula Mining License. Drill hole DD1450 intersection includes grades of up to 40% copper and is within 190 meters of surface. DD1450 is the thickest, highest-grade copper intersection drilled to date (January 30, 2019 Press Release) at Kamoa-Kakula. It highlights the potential for important additional resource expansion.

Ivanhoe Mines Ltd. (IVPAF), closed Friday's trading session at $2.46, down 1.20%, on 125,503 volume with 154trades. The average volume for the last 3 months is 136,071 and the stock's 52-week low/high is $1.50/$2.77.

chart

Great Bear Resources Ltd. (GTBDF)

Proactive Investors, Penny Stock Tweets, Connecting Investor, Gold Stock Data, Stockhouse, Capital Cube, Stock Digest, MoneyShow, Market Screener, Wallet Investor, The Stock Market Watch, Dividend Investor, InvestorsHub, Wallmine, Junior Mining Network, Bitcoin & Stock Journal, Streetwise Reports - The Gold Report, Trading View, MarketWatch, Seeking Alpha, Investors Hangout, Investing News, Street Insider, Resource World, Morningstar, YCharts, The Street, Streetwise Reports, and GuruFocus reported on Great Bear Resources Ltd. (GTBDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Great Bear Resources Ltd. is a mineral exploration company listed on the OTC Markets’ OTCQB. It engages in the acquisition and exploration of mineral properties in Canada. The Company’s flagship Dixie property is roughly 15 minutes' drive along Highway 105 from downtown Red Lake, Ontario. The Dixie property covers a drill and geophysically defined 10-kilometer gold mineralized structure alike to that hosting other producing gold mines in the district. Great Bear Resources has its corporate office in Vancouver, British Columbia.

Furthermore, the Company is earning a 100 percent royalty-free interest in the West Madsen, Pakwash, Dedee and Sobel properties. These cover regionally significant gold-controlling structures and prospective geology. All of Great Bear Resources’ Red Lake projects are accessible year-round via existing roads. The Red Lake mining district has produced more than 30,000,000 ounces of gold. It is one of the premier mining districts in Canada.

Great Bear Resources has 100 percent ownership and no royalties on 13,000 hectares in a tightly held company. The Company holds 100 percent of 9,140 hectares prospective greenstone belts at Dixie with no royalties. Gold is confirmed along a 2.3 km strike of a 10 km target. The System is open along strike and at depth. The ongoing drill program is 30,000 meters of 150 holes, through this year.

Regarding the West Madsen Project it is an on-strike extension of Pure Gold’s high-grade Madsen project. Recent expansion is 1136 hectares; 3,860 hectares for all of West Madsen. The Geophysical Survey shows two main gold targets: a prominent northeast to southwest magnetic linear and strong evidence of large-scale folding. Company plans for this year at West Madsen include geological mapping, rock sampling, prospecting, as well as drill target generation.

Last month, Great Bear Resources reported drill results from the Dixie Hinge Zone (DHZ) at its Dixie Project in the Red Lake District of Ontario. The Company discovered one of the widest near-surface occurrences of veining and alteration hosting high-grade gold reported on the project so far. Additionally, it has successfully extended the Hinge Zone at depth.

Mr. Chris Taylor, Great Bear Resources’ President and Chief Executive Officer, said, "We continue to be surprised by the strength and scale of the gold system at Dixie. Our latest drilling shows the Hinge Zone vein and alteration system swells to 138 feet (42 meters) in approximate true width, includes individual veins over 45 feet (14 meters) in width, and contains multiple gold-bearing veins in 4 of the latest 8 drill holes. We will continue to drill to extend the strike length, depth, and number of gold zones at the Dixie Hinge through 2019 and 2020.

This week, Great Bear Resources reported drill results from reconnaissance drilling to the west of the Dixie Hinge Zone (DHZ) at its Dixie Project, and the acquisition of new district properties covering additional gold mineralization targets. Two exploratory drill fences were completed 150 meters and 400 meters west of the current DHZ drilling, along the D2 fold axis interpreted to be a significant gold control, using the recently added second drill rig.

Great Bear Resources reported new low-cost, royalty-free property acquisitions adding to its strategic land positions in the Red Lake District of Ontario. These newly acquired properties will be mapped and prospected this summer, with marginal impact on Great Bear's present Dixie property exploration budget and program.

Great Bear Resources Ltd. (GTBDF), closed Friday's trading session at $2.2516, down 1.25%, on 41,777 volume with 43 trades. The average volume for the last 3 months is 37,767 and the stock's 52-week low/high is $0.335/$3.089.

chart

Acro Biomedical Co., Ltd. (ACBM)

Connecting Investor, Penny Stock Hub, Stockwatch, Stock Digest, Simply Wall St, Market Screener, MarketWatch, GuruFocus, Barchart, GlobeNewswire, Wallmine, Bitcoin & Stock Journal, Last10k, YCharts, Morningstar, InvestorsHub, Trading View, Stockhouse, The Street, Credit Risk Monitor, Stockopedia, Wallet Investor, Dividend Investor, Seeking Alpha and Nasdaq reported on Acro Biomedical Co., Ltd. (ACBM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Acro Biomedical Co., Ltd. focuses on developing and marketing products that promote wellness and a healthy lifestyle. Its intention is to conduct research and development (R&D) on its own proprietary products based on cordyceps sinensis. The Company previously went by the name Killer Waves Hawaii, Inc. It changed its name to Acro Biomedical Co., Ltd. in January of 2017. Acro Biomedical is based in Fishers, Indiana.

Cordyceps sinensis has been described as a medicine in old Chinese medical books and Tibetan medicine. Cordyceps sinensis is a rare combination of a caterpillar and a fungus. It is found at altitudes above 4500m in Sikkim. Acro Biomedical originated from a group of scholars at the University of Taiwan. The Founder, Mr. Richard Chu, was looking for the materials for disease treatment and health care from traditional Chinese medicine and natural herbal medicine. The preferred material is China treasure, "Cordyceps".

The Company will operate in two main areas. These are health food development and new drug development. The first decade of Acro Biomedical was the development of scientific research to establish a combination of basic science. Since the founding of the Company, the target has always been scientific applications and market development.

The objective of establishing a technology and market integration business model centers on diverse areas. These include China, Southeast Asia, Northeast Asian, Central Asian and the Europe and United States market. Moreover, there are two special markets, one for the Chinese health industry market and one for the longevity of health care market.

In late December 2018, Acro Biomedical reported financial results for the year ended September 30, 2018. The Company generated revenue of $8.0 million and realized record Gross Profit in fiscal year 2018 of $0.83 million. Acro also generated positive Net Income of $0.42 million.

Revenue for the year ended September 30, 2018 was the above-mentioned $8.0 million, which represents an increase of $7.5 million versus $510,000 for the year ended September 30, 2017. Acro Biomedical did not generate any Revenue before Q4 of the year ended September 30, 2017.

Acro Biomedical Co., Ltd. (ACBM), closed Friday's trading session at $4.11, even for the day, on 6,200 volume with 6 trades. The average volume for the last 3 months is 1,552 and the stock's 52-week low/high is $2.269/$4.92.

chart

GGX Gold Corp. (GGXXF)

Jet Life Penny Stocks, Junior Mining Network, The Street, Penny Stock Hub, Wall Street Pennies, Stockwatch, Wallet Investor, 4-Traders, Barchart, Resource World, Proactive Investors, Dividend Investor, Mining Capital, MarketWatch, Wallmine, Investment Pitch, OTC Markets, YCharts, Investors Hangout, GuruFocus and Stockhouse reported beforehand on GGX Gold Corp. (GGXXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

GGX Gold Corp. is a gold exploration company listed on the OTCQB. It is rejuvenating an historic British Columbia gold camp with new discoveries. The Company previously went by the name Revolver Resources, Inc. It changed its name to GGX Gold Corp. in October 2016. GGX Gold has its corporate headquarters in Vancouver, British Columbia.

The Company’s Gold Drop project encompasses an area of greater than 5,600 hectares. The Gold Drop Project is positioned 40 km from Grand Forks, British Columbia on geologically prospective ground in the well-mineralized Greenwood Mining District. GGX Gold has discovered two new significant gold bearing vein structures - the C.O.D. and Everest veins. Also, GGX owns nine percent of a private syndicate centered on project generation within the Golden Triangle.

Drilling and trenching during the 2017 exploration season and the 2018 season have led to the discovery of significant gold bearing structures. These structures are predominant throughout the property. Gold Drop’s historical production totals 7572 tonnes at an average grade of 5.2 g/t Au and 93.4 g/t Ag. The 7572 tonnes was mined from three main veins - Amandy, North Star and Gold Drop.

Recently, GGX Gold summarized highlights of the 2018 exploration season on the Gold Drop Property in Southern British Columbia. The program concentrated on the C.O.D vein in the Gold Drop Southwest Zone. During the drilling program GGX also conducted mechanical trenching on manifold targets.

The Company completed 71 diamond drill holes on the C.O.D vein. High-grade intersections include 107.5 g/t gold and 880 g/t silver over 6.90 meters core length and 129 g/t gold and 1,154 g/t silver over 7.28 meter core length. GGX extended the C.O.D vein 160 m to the southwest via drilling.

The Company completed 19 diamond drill holes on the Everest vein. In addition, it discovered the southern extension of the Gold Drop vein via mechanical trenching. It also completed 30 m of trenching on the Silent Friend Vein. GGX completed a thorough trenching program in the C.O.D North area of the property.

This month, GGX Gold announced it requested tellurium re-analysis of select drill core samples from the Fall 2018 diamond drill program at the Gold Drop Property in southern British Columbia. The Fall 2018 drill program was conducted at the C.O.D. Vein in the Gold Drop Southwest Zone. Numerous drill core samples from drill holes COD18-67 and COD18-70 surpassed the upper 500 grams per tonne (g/t) analytical limit for tellurium. The samples returned high grade values for gold and silver. These samples will be re-analyzed to ascertain tellurium grades.

GGX Gold Corp. (GGXXF), closed Friday's trading session at $0.0731, down 8.62%, on 13,500 volume with 1 trade. The average volume for the last 3 months is 12,478 and the stock's 52-week low/high is $0.043/$0.108.

chart

Molori Energy, Inc. (MOLOF)

Awesome Stock Picks, Zacks, OTC Markets, Stockhouse, Streetwise Reports, InvestorsHub, and MarketWatch reported on Molori Energy, Inc. (MOLOF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

An oil and gas production enterprise, Molori Energy, Inc. has current operations in the Texas Panhandle West Field. Its operating team based in Borger, Texas has extensive experience in the oil and gas industry in the Texas Panhandle. Molori Energy's business model is to deliver sustainable growth in shareholder value through centering on exploiting its existing reserves, commercializing and developing discoveries, and pursuing selective acquisitions.

Molori Energy has its corporate office in Vancouver, British Columbia. The Company previously went by the name Taipan Resources, Inc. It changed its name to Molori Energy, Inc. in January of 2017. The Company lists on the OTC Markets.

Molori Energy’s strategy has been to engage in low-risk well reactivations in the Texas Panhandle to produce steady cash flows. Greater than 60 wells have been reactivated to date. These are producing from the prolific Brown Dolomite formation. Molori owns a 25 percent Working Interest (WI) in certain leases positioned in the bifurcated Texas panhandle, operated by its Texas-based partner Ponderosa Energy, LLC.

Molori has 165 producing (PDP) wells and an inventory of about 202 non-producing wells (PDNP) for a total of 367 wells. The Company is working to RTP (Return to Production) the PDNP wells through performing simple re-works or re-completions.

In February 2018, Molori Energy announced a commercial oil discovery on its acreage in Moore County, Texas. The "Thompson 23-1R" well, operated by Molori, is a northern step-out well drilled in December 2017. The Thompson 23-1R well is directly north of the active development area of Adams Affiliates.

Molori Energy earlier signed an LOI (Letter of Intent) to purchase a 100 percent WI of which the Company will be the operator of record in an additional roughly 5,100 gross acres of land in Moore, Potter, and Carson Counties, north Texas. With the agreement, Molori is to hold a 100 percent WI in the leases, some of which border lands where Adams Affiliates of Tulsa, Oklahoma is now developing oil and gas production from the Red Cave formation. The roughly 5,100 acres are now held by production (HBP). They contain a 75 percent NRI (Net Royalty Interest).

In July, Molori Energy provided an update concerning its operations in Moore County and Hutchinson County, Texas. The Company announced on May 7, 2018, the first of two Letters of Intent (LOIs) to acquire a 100 percent Working Interest (WI) in roughly 30,000 acres with access to the Red Cave and other formations.

The acreage, in Moore, Potter, Carson and Hutchinson counties, is HBP (Held By Production). It includes 8 currently-producing wells. The agreement calls for the payment of USD $1,700,000 in cash on closing. Molori announced on May 22, 2018, the second LOI for the purchase of a 100 percent WI in an additional 5,100 acres in the Red Cave formation.

Molori Energy, Inc. (MOLOF), closed Friday's trading session at $0.031, up 2.96%, on 2,000 volume with 1 trade. The average volume for the last 3 months is 24,746 and the stock's 52-week low/high is $0.0186/$0.2689.

chart

ProGreen US, Inc. (PGUS)

Amigo Bulls, Market Exclusive, Marketwired, Uptick Newswire, Investors Hangout, Insider Financial, Penny Stock Prodigy and Promotion Stock Secrets reported previously on ProGreen US, Inc. (PGUS), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

ProGreen US, Inc. engages primarily with investments in agricultural and real estate projects in Baja California, Mexico. The Company is focusing on intensifying its property investments in Baja California, Mexico, via its joint venture (JV) partnership with Inmobiliaria Contel, and through its subsidiary Procon Baja JV. ProGreen US has its corporate office in San Diego, California.

Regarding ProGreen US’s Baja Project, the Company entered into a JV with a Mexican landowner, Inmobiliaria Contel and has jointly created Pro Baja. This is its newest JV with ProGreen owning 51 percent and Inmobiliaria Contel 49 percent. ProGreen US established an office location in Ensenada. It serves as headquarters for all of its activities in Baja California.

Procon and Contel operate from this location. Contel is currently active in the high margin produce industry, growing crops for exporters to the U.S. market, with an abundance of land available for expansion under its JV partnership.

Procon has acquired 5,100 acres of land with 4.7 miles of oceanfront on the Bay of El Rosario, for which a master plan is being drawn for the development of a very large, completely green, international vacation and retirement community named "CieloMar." ProGreen US completed development of the first tract of land, which consists of approximately 300 acres. Of this, some 100 usable acres were cleared.

ProGreen US previously signed another agreement for a further 1,900 acres (500-800 usable for farming), and a 3-year option for 11,500 acres (1000-2500 usable for farming). The land, once developed and prepared, will be offered for long term lease (10-15 years), with the JV holding the title.

ProGreen US earlier started the process of obtaining the certification of its agriculture operations in Baja California, for direct export. This is so it can sell the ProGreen Farms™ produce directly to prospective U.S. buyers.

Recently, ProGreen US announced that it's subsidiary, Procon Baja JV (Procon), closed on the purchase and took possession of the new 2,500-acre tract of land in Baja California. The total purchase price is $160,000 (USD).

In July, ProGreen US announced that the Phase I Execution Plan for Cielo Mar was completed for presenting to authorities in July. The Phase I Execution Plan presentation included an overview drawing, many additional drawings, the detailed environmental impact statement, photos, videos and other information. The presentation of the plan to the authorities was a major milestone for the Cielo Mar development. Upon Approval (indicated to be September-October), the land will be changed from "rustic" to "development" land. Then, work on the infrastructure can commence within weeks.

In August, ProGreen US announced that red chili peppers from the ProGreen Farms™ operation in Baja California were now being delivered to Huy Fong Foods, Inc., maker of the original Sriracha chili sauce, in Irwindale, California. The Company's U.S. distribution subsidiary, ProGreen Farms US, LLC, imports produce from the Rancho Arenoso farm, near El Rosario, Baja California, Mexico.

ProGreen Farms™ Rancho Arenoso is growing chili peppers on the roughly 100 acres now being farmed. It has plans for diversifying the operation with other kinds of produce for U.S. buyers as it expands onto the close by 2,500 acres, which ProGreen's Mexican subsidiary, Procon Baja JV, acquired this past June.

ProGreen US, Inc. (PGUS), closed Friday's trading session at $0.0015, up 25.00%, on 8,018,551 volume with 48 trades. The average volume for the last 3 months is 37,939,053 and the stock's 52-week low/high is $0.0007/$0.0392.

chart

Fortescue Metals Group Limited (FSUMF)

InvestorsHub, YCharts, Equity Clock, OTC Markets, Marketbeat, TradingView, and InvestorVillage reported on Fortescue Metals Group Limited (FSUMF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Fortescue Metals Group Limited is a global leader in the iron ore industry. The Company has grown to be one of the largest international iron ore producers. At present, it produces 170 million tonnes of iron ore annually. Fortescue Metals Group’s shares trade on the OTC Markets Groups OTCQX. Established in 2003, the Company is based in East Perth, Australia.

Fortescue Metals owns and operates integrated operations covering three mine sites in the Pilbara, the five berth Herb Elliott Port in Port Hedland, and the fastest, heavy haul railway worldwide. The Company now supplies 17 per cent of China’s seaborne iron ore. Fortescue has a fleet of four Fortescue Ore Carriers. Four more are to be delivered in Fiscal Year (FY) 2018.

Fortescue Mining is the first company in Western Australia to control a railway from outside a region of operation. Fortescue Metals wholly owns and operates its purpose designed rail and port facilities. These were built to deliver iron ore from its mines to Port Hedland and on to its customers. The Company’s railway covers 620 kilometers of track.

In addition, it is the first company in the world to use CAT autonomous haulage technology on a commercial scale. Fortescue continues to undertake early stage, low cost exploration on coppergold prospective tenements in South Australia and New South Wales. Moreover, it has assessed high potential, early stage exploration tenements in Ecuador, where it was granted 32 exploration areas.

Fortescue Metals also has its Iron Ore Projects. Its Iron Bridge Project is 100 kilometers south of Port Hedland. This is a JV between Fortescue Metals Group, Taiwan’s Formosa Group, and China’s Baosteel Group, incorporating the world class North Star and Glacier Valley Magnetite ore bodies. Fortescue’s Iron Ore Projects also include the Firetail Replacement Project. Firetail is an important element of the Fortescue Blend product.

Fortescue Metals has expanded autonomous haulage at Chichester Hub. The Chichester Hub in the Chichester Ranges, comprising the Cloudbreak and Christmas Creek mines, has a yearly production capacity of 100mtpa from three Ore Processing Facilities (OPF).

The expansion of its autonomous haul fleet has marked a significant milestone, with the first trucks fitted with Autonomous Haulage Technology (AHS) currently in operation at Christmas Creek. The conversion of about 100 haul trucks at the Chichester Hub will see Fortescue Metals Group become the first iron ore operation in the world to have a fully autonomous fleet.

Additionally, the Company’s operations include The Solomon Hub in the Hamersley Ranges. The Solomon Hub is situated 60 kilometers north of Tom Price and 120 kilometers to the west of Fortescue Metals’ Chichester Hub.

Fortescue Metals Group Limited (FSUMF), closed Friday's trading session at $4.55, up 0.44%, on 1,000 volume with 3 trades. The average volume for the last 3 months is 8,953 and the stock's 52-week low/high is $2.53/$4.73.

chart

AXIM Biotechnologies, Inc. (AXIM)

Stockhouse, InvestorsHub, Barchart, SmallCapVoice, Streetwise Reports, OTC Markets, MarketWatch, Metals News, and StockoftheWeek reported on AXIM Biotechnologies, Inc. (AXIM), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

AXIM Biotechnologies, Inc. is a biotechnology company concentrating on the research, development, and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products. The Company discovers and brings to market unique solutions by way of research and development (R&D), strategic partnerships, and acquisitions through setting the green standard in the industrial hemp industry. Medical Marijuana, Inc. (MJNA) is a major investor in AXIM. OTCQB-listed, AXIM Biotechnologies is based in New York, New York.

The Company’s focus is on innovative proprietary delivery mechanisms for the introduction of cannabinoids and finding solutions for conditions for which there is currently no effective treatment. AXIM is advancing its patented controlled-release cannabinoid gum in studies encompassing several indications.

AXIM’s flagship CanChew Plus® contains 10mg of cannabidiol (CBD) obtained from industrial hemp plants. The Company also has its CanChew+ 50®, which contains 50 mg of CBD. This product is undergoing clinical trials in patients with IBS (Irritable Bowel Syndrome).

Additionally, AXIM Biotechnologies’ pipeline of Intellectual Property (IP) protected cannabinoid-based products includes MedChew Rx™. This THC/CBD cannabinoid controlled-release chewing gum is to address pain and muscle spasticity in multiple sclerosis (MS) patients. It is the world’s first patented cannabinoid controlled-release chewing gum.

The Company’s IP portfolio now includes two fully issued patents – one patent permitting the use of CBD (cannabidiol) in controlled-release, functional chewing gum, and another patent for chewing gum containing natural and synthetic cannabinoids for the treatment of pain, and 15 patent applications in different stages of approval.

At the end of February 2018, Medical Marijuana, Inc. (MJNA) announced that its major investment company AXIM Biotechnologies successfully executed its first-ever proprietary current good manufacturing practices (cGMP) methodology in the extraction and microencapsulation of cannabinoid molecules for an array of pharmaceutical delivery formats from cGMP-produced medicinal cannabis.

This breakthrough makes AXIM the only Company globally with the ability to harness the proprietary procedure and provide Active Pharmaceutical Ingredients (APIs) of such purity from naturally extracted cGMP sources.

AXIM Biotechnologies, Inc. (AXIM), closed Friday's trading session at $1.425, up 1.06%, on 109,101 volume with 163 trades. The average volume for the last 3 months is 187,086 and the stock's 52-week low/high is $0.46/$6.96.

chart

First Choice Healthcare Solutions, Inc. (FCHS)

007 Stock Chat, PennyStockSpy, Greenbackers, StocksImpossible, TheMicrocapNews, First Penny Picks, Marketbeat.com, and OTCBB Journal reported on First Choice Healthcare Solutions, Inc. (FCHS), and we also report on the Company, here at the QualityStocks Daily Newsletter.

First Choice Healthcare Solutions, Inc. (FCHS) engages in owning and operating multi-specialty (non-physician-owned) medical centers of excellence throughout the southeastern United States. The Company is one of the nation's only non-physician-owned, publicly traded healthcare services enterprises centered on the delivery of total musculoskeletal solutions with a concentration on Orthopaedic and Spine care. FCHS has its head office in Melbourne, Florida.

The Company’s devotion is to deliver clinically superior, patient-centric care. Its flagship integrated platform currently administers greater than100,000 patient visits annually. It consists of First Choice Medical Group, The B.A.C.K. Center, and Crane Creek Surgery Center.

FCHS medical centers of excellence focus on treating patients in different specialties. These include Orthopaedics, Spine Surgery, Neurology, Interventional Pain Management, as well as related diagnostic and ancillary services.

First Choice Medical Group (Melbourne, Florida) is the Company’s flagship multi-specialty medical center of excellence. First Choice Medical Group specializes in the delivery of musculoskeletal medicine and rehabilitative care with manifold quality-focused goals focused on enriching its patients’ care experience.

FCHS has expanded its portfolio of Medical Centers of Excellence in the Florida Space Coast region, with its Brevard Orthopaedic Spine & Pain Clinic, Inc., dba The B.A.C.K. Center. The B.A.C.K. Center is a leading, advanced orthopaedic spine and pain practice in Brevard County, Florida. Its emphasis is on Spinal Care & Surgery; Non-Operative Spine Procedures; Chiropractic Services; Osteoporosis Care; Acupuncture; and Interventional Pain Management.

FCHS’s Crane Creek Surgery Center is an AAAHC accredited facility. Its dedication is to deliver first-rate, ambulatory surgical care in a convenient, comfortable outpatient environment. The 18,000-plus sq. ft. facility is in Melbourne, Florida within the Crane Creek Medical Center building. This building is also home to The B.A.C.K. Center.

In February, FCHS announced that one of its wholly-owned subsidiaries, CCSC Holdings, Inc. acquired an additional 25 percent ownership interest in Crane Creek Surgery Center. This brings its total ownership interest to 65 percent. Furthermore, CCSC Holdings has assumed management responsibility of Crane Creek and ended the earlier agreement with NueHealth.

Recently, FCHS announced the closing of its strategic partnership with Steward Health Care System. Steward is the largest private hospital operator in the U.S. This closing was formalized with Steward Health Care System’s investment of $7.5 million in exchange for 5 million shares of FCHS stock.

Mr. Chris Romandetti, FCHS’ President and Chief Executive Officer, stated, "The finalization and closing of this strategic partnership with Steward provides excellent momentum for all parties involved.  An investment of this magnitude allows First Choice to expeditiously continue to rollout our unique and proven delivery platform among Steward’s nationwide network….”

First Choice Healthcare Solutions, Inc. (FCHS), closed Friday's trading session at $0.38, up 2.70%, on 13,100 volume with 4 trades. The average volume for the last 3 months is 25,456 and the stock's 52-week low/high is $0.155/$1.44.

chart

MamaMancini's Holdings, Inc. (MMMB)

TheMicrocapNews, TaglichBrothers, Stock News Now, SmallCapVoice, Marketbeat.com, and OTC Markets Group reported earlier on MamaMancini's Holdings, Inc. (MMMB), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

MamaMancini's Holdings, Inc. is a marketer of specialty pre-prepared, frozen, and refrigerated all natural food products (as defined by the United States Department of Agriculture - USDA). The Company is a marketer and distributor of a line of beef meatballs and turkey meatballs all with sauce, five cheese stuffed beef and turkey meatballs all with sauce, original beef and turkey meatloaves, chicken parmesan, stuffed peppers, and other like Italian cuisine products. MamaMancini’s Holdings is headquartered in East Rutherford, New Jersey.

MamaMancini's distribution channel includes major retailers and distributors, including Costco, Publix, Shop Rite, Jewel, Save Mart, Lucky's, Lunds and Byerlys, SuperValu, Safeway, Albertsons, SpartanNash, Bashas, Whole Foods Market, Hy-Vee, Sam's Club, and Shaw's. Major retailers and distributors also include Kings, Roche Bros., Key Foods, Stop & Shop, Giant, Giant Eagle, Foodtown, Kroger, Shoppers, King Kullen, Lowes, Central Market, Weis Markets, Ingles, Food City, The Fresh Market, Sysco, Burris Foods, C&S, and Driscoll Foods.

In addition, the Company sells an assortment of its products on air and online on QVC, which is the world's largest direct to consumer marketer.

MamaMancini's offers Slow Cooked Italian Sauce and Meatballs, Stuffed Meatballs, Slow Cooked Sauces, Slow Cooked "Italian Style Sauce" and Meatballs - Gluten Free, Slow Cooked Italian Sauce and Meatballs made without Antibiotics, bacon gorgonzola beef meatloaf, and its Italian Style Meatloaf. It also has Food Service offerings and offers Bulk Deli Orders.

In August, MamaMancini's Holdings announced that it signed a Letter of Intent (LOI) to acquire Joseph Epstein Food Enterprises, Inc. (JEFE), a manufacturer of food products, which has been the sole manufacturer of MamaMancini’s products since inception. Under the agreed terms, no cash would be exchanged between the parties. JEFE is currently owned by the Chief Executive Officer and President of MamaMancini's Holdings, who in total owns roughly 44 percent of the Company's common stock.

Recently, MamaMancini's Holdings announced financial results for Q2 of fiscal year 2018, ended July 30, 2017. Q2 of fiscal year 2018 Revenue increased 69 percent to $7.0 million versus $4.1 million in the previous year period. Net Income for the second quarter was $24,000 in comparison to a Net Loss of $(277,000) in the previous year period. This represents a $301,000 improvement.

Net Loss available to common stockholders was $(5,000), or $0.00 per diluted share, during Q2 of fiscal 2018, versus a Net Loss of $(324,000), or $(0.01) per diluted share in the same quarter the year prior.

MamaMancini's Holdings also recently announced that its Beef and Turkey Stuffed Meatballs were voted by the QVC Shopping Network audience as the #1 product in the 'Quick and Easy Meals' category during QVC's 2017 Audience Choice Awards Program, yesterday September 13, 2017.

MamaMancini's Holdings, Inc. (MMMB), closed Friday's trading session at $0.705, up 0.70%, on 200 volume with 1 trade. The average volume for the last 3 months is 12,706 and the stock's 52-week low/high is $0.46/$1.32.

chart

Surna, Inc. (SRNA)

Hot Stock Profits, Ascending Stocks, Promotion Stock Secrets, Wall Street Mover, TopPennyStockMovers, Marketbeat, CFN Media Group, PennyStockRumors, DSR News, PricelessPennyStocks, Value Penny Stocks, Cannabis Financial Network News, SmallCapVoice, Greenbackers, PHUB News, Actual Gains, OTC Stock Review, and Market Wire Stocks reported on Surna, Inc. (SRNA), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Surna, Inc. develops, acquires, produces, and sells equipment for the legal marijuana industry. It develops innovative technologies and products to monitor, control, and address the energy and resource intensive nature of indoor cannabis cultivation. The Company’s mission is to acquire intellectual property (IP) and scalable operating companies in the nascent, legal marijuana industry with a focus on disruptive technology, equipment, as well as related support services. OTCQB-listed, Surna is based in Boulder, Colorado.

A technology business, the Company’s goal is to dominate the infrastructure, growing, and support side of the worldwide cannabis industry. The foundation of Surna’s present revenue stream is on its chief product offerings - supplying industrial technology and products to commercial indoor cannabis grow facilities.

Surna engineers, manufactures, and distributes state-of-the art equipment and systems for Controlled Environment Agriculture (CEA). Currently, the Company’s specialty is commercial indoor cannabis cultivation. Its business model excludes the production or sale of marijuana. Via its wholly-owned subsidiary, Hydro Innovations, Surna provides a complete line of commercial and small business indoor agriculture equipment.

Surna has its signature water-cooled climate control platform. It has filed a provisional patent application covering enhancements to its proprietary Climate Control Systems and Methods used in indoor gardens. The patent includes an industrial process that provides electricity, heating, and cooling while utilizing the resulting carbon-dioxide (CO2) produced as a nutrient for the plants.

Surna’s intention is to integrate this and other proprietary technology into a new, commercial-grade power-generating and environmental control system product. The system is undergoing design to provide a near zero waste energy alternative for the cannabis industry.

Regarding Services, Surna provides an array of services to help from project inception to post production maintenance. These services include consulting, engineering, bio-security, odor control, and installation support. The Company also offers its product family. These products are for climate control, automation, and biosecurity.

Surna also offers its hybrid building solution as well as parts and accessories. The design of its hybrid building is for efficiency. This is Surna’s turnkey solution that keeps one’s facility sealed while reducing energy consumption.

Surna, Inc. (SRNA), closed Friday's trading session at $0.066, even for the day, on 248,141 volume with 39 trades. The average volume for the last 3 months is 401,416 and the stock's 52-week low/high is $0.05/$0.29.

chart

The QualityStocks Company Corner

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

NetworkNewsAudio announces the Audio Press Release (APR) titled “Making Profits, Saving Lives with Gene Therapy,” featuring Genprex Inc. (GNPX). To hear the NetworkNewsAudio version, visit: http://nnw.fm/bw1cX. To read the full editorial, visit: http://nnw.fm/Y0ZqH. Also today, NetworkNewsWire released a report on the company detailing how GNP is at the forefront of the battle, testing its trademarked Oncoprex immunogene therapy as a means of combating lung cancers.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (OTC: GNPX), closed the day's trading session at $2.10, off by 2.33%, on 423,091 volume with 1,381 trades. The average volume for the last 3 months is 36,740 and the stock's 52-week low/high is $0.95/$19.45.

Recent News

chart

City View Green Holdings Inc. (CSE: CVGR)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR).

City View Green Holdings (CSE: CVGR) is focused on assessing and potentially acquiring targets in the cannabis industry through diversification. To view the full article, visit: http://nnw.fm/72Nzb.

City View Green Holdings Inc.'s (CSE: CVGR) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Management

Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR), closed the day's trading session at $0.14, off by 12.50%, on 480,264 volume with 63 trades. The average volume for the last 3 months is 934,880 and the stock's 52-week low/high is $0.14/$0.465.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Innovative biotechnology company Earth Science Tech (OTCQB: ETST) is looking to expand to wider U.S. markets and has reached strategic agreements to sell its CBD product line to chiropractors, dispensaries, pharmacies, healthcare practitioners, athletic clubs and clinics throughout the country (http://nnw.fm/76CTl). To view the full article, visit: http://nnw.fm/9W1xX.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.72, up 5.88%, on 63,983 volume with 29 trades. The average volume for the last 3 months is 31,673 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

chart

Kontrol Energy Corp. (CSE: KNR) (OTC: KNRLF) (FSE: 1K8)

The QualityStocks Daily Newsletter would like to spotlight Kontrol Energy Corp. (CSE: KNR).

Based in Vaughan, Ontario, Kontrol Energy Corp. (CSE: KNR) (OTC: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector via IoT (Internet of Things), cloud and SaaS (Software as a Service) technology. The company integrates smart-energy devices, energy software and energy retrofits to help organizations benefit from energy cost savings while reducing greenhouse gas emissions. Kontrol offers its SmartMax intelligent energy technology. Recently, Kontrol Energy was named as the seventh-fastest growing start-up in Canada in 2018 by Canadian Business and Maclean's.

Kontrol Energy Corp. (CSE: KNR) (OTC: KNRLF) (FSE: 1K8) specializes in the integration of smart energy technologies and solutions for North American commercial and industrial property owners and operators to help them benefit from energy cost savings and minimize greenhouse gas emissions. Kontrol is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology and is ranked by Canadian Business and Maclean’s as the 7th fastest growing startup in 2018.

Kontrol’s leadership position is reshaping the way customers use, manage and strategically allocate energy resources to realize immediate energy savings by gaining more control over energy consumption and demand in real-time.

As the fastest growing global “fuel source,” energy efficiency is big business with industry analysts noting this multi-trillion-dollar market offers significant opportunities over the next five years. Established market segments include: energy retrofits ($71.4 billion); distributed generation ($179.9 billion); energy analytics ($33.5 billion); and greenhouse gas/carbon measurement, reduction ($1.2 trillion). Each $1 invested in energy efficiency displaces up to $3 of utility-scale transmission and distribution investment, according to the International Energy Agency.

Formed in 2015 by a group of energy veterans who recognized that the energy efficiency industry is one of the fastest growing fuel sources for the global economy, Kontrol is committed to enhancing and improving its customers sustainability objectives. In less than two years, Kontrol has grown its revenue run rate to $16 million from $1.8 million, delivering on stated goals and objectives as it seeks to continue this pattern through accretive acquisitions and the expansion of the company’s smart energy technologies.

Up to 50 percent of Kontrol’s overall revenues are recurring annually, and the company’s 2019 outlook includes strategic initiatives that will expand the company’s smart energy technologies to U.S. markets, bring additional accretive and strategic acquisitions, and accelerate recurring SaaS revenues.

Kontrol’s strategy of disciplined mergers and acquisitions includes the following highlights:

  • Acquisition of Log-One Ltd.’s award-winning energy conservation technology, Energy Management System (“EMS”), an intelligent, occupancy-based heating and air-conditioning control system for commercial and multi-residential real estate. Rebranded as Kontrol EMS Technology, the company has added IoT and mobile application capabilities, creating a recurring revenue platform through a Software-as-a-Service (SaaS) platform.
  • Acquisition of ORTECH Consulting Inc., an engineering consulting firm specializing in Greenhouse Gas (GHG) reporting, emission testing, air quality testing and renewable energy/power consulting.
  • Acquisition of Efficiency Engineering Inc. (“EE Inc.”), which provides engineering services to industrial, municipal and commercial building owners across Canada. EE Inc. provides detailed energy efficiency analysis, energy audits, management of facility system solutions, electrical and mechanical design and energy conservation studies.
  • Acquisition of MCW Dimax Ltd. (“MCX”), a firm specializing in solutions for the application of energy software to analyze the management of complex heating, ventilation and cooling systems for large residential, commercial, and mission critical real estate owners.
  • Acquisition of CEM Specialties Inc. (“CEMSI”), a market leader in turn-key emission monitoring, equipment and solutions.

The company has also established entry into the North American cannabis market as a supplier of integrated energy efficiency solutions and technologies. Within this market, Kontrol is focused on assisting cannabis growers to reduce the cost of energy and support mission critical infrastructures. To date, Kontrol has secured two contracts to provide energy efficiency services with Licensed Producers in the Canadian cannabis sector.

The Kontrol Energy group of companies is currently saving its customers more than 40 million kilowatt hours of electricity per annum and providing a corresponding reduction in GHG emissions.

Kontrol’s management team includes CEO Paul Ghezzi, a leader in clean tech, renewable energy development, solar project financing and distributed generation. Ghezzi has global experience in power generation projects under Feed-in Tariff programs and Power Purchase Agreement programs for both commercial and utility-scale projects. COO Kristian Lavereau has more than 25 years of experience in the IT solutions (analytics and mobile computing), energy optimization and efficiency (intelligent control systems, solar PV, lighting). Claudio Del Vasto, CPA, CA | CFO, is a senior finance executive with an extensive background in corporate finance, strategy and business development.

Kontrol Energy Corp. (CSE: KNR), closed the day's trading session at $0.78, up 14.71%, on 192,715 volume with 77 trades. The average volume for the last 3 months is 21,068 and the stock's 52-week low/high is $0.46/$0.99.

Recent News

chart

Green Hygienics Holdings Inc. (GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (GRYN).

Full-scope, premium cannabis company Green Hygienics Holdings (OTCQB: GRYN) is capitalizing on its proprietary aeroponics-based techniques to stand out in the budding cannabis industry and emerge as a science-driven cultivation leader. To view the full article, visit: http://nnw.fm/r0Wf1.

Green Hygienics Holdings Inc. (GRYN) is a full-scope, premium cannabis cultivation company targeting the high-end medical and adult-use recreational market. With more than 25 years of experience in agricultural science and innovation, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company will grow by generating revenues from the sales of premium grade cannabis products, developing and licensing valuable IP, making strategic acquisitions, and creating trusted global consumer brands.

The company has integrated and is developing its own IP assets related to proprietary systems and apparatus, software, algorithms and custom-engineered hardware. This provides ultimate efficiencies in a commercially controlled cultivation environment. Utilizing the advantages of hybrid-aeroponics, Green Hygienics creates a sterile growing environment that produces consistent, high-quality product while maintaining the lowest possible carbon footprint. The company utilizes state-of-the-art, quality-controlled commercial cultivation methodology to assure production of pharmaceutical-grade cannabis at much higher yields and greatly reduced costs.

Hybrid-aeroponics produces quality cannabis faster than traditional methods since it doesn’t require natural sunlight or soil and can be operational and produce plants anywhere. Plants grown under aeroponic conditions receive water and nutrients directly to their roots via a fine mist in a controlled environment, dramatically reducing spoilage while keeping the product organic and the environment pest-free. The plants are given the exact amount of nutrients and moisture precisely when needed. Green Hygienics maintains ultimate control over every aspect of this cultivation process, which allows the company to operate with conservation of natural resources in mind. The technology that uses 90-95 percent less water and does not require the use of pesticides or fungicides.

Additionally, the company’s state-of-the-art engineered, controlled environments include electrical, mechanical and HVAC designs that meet mandatory fire and energy codes while improving energy efficiency significantly.

Through these practices, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company continues to develop and incubate software as well as engineer hardware to provide additional control over the commercial cultivation method. The company’s science-based approach reveals any growth anomalies before the human eye can see them. This makes it possible to monitor all facets of production, identify cultivation problems based upon scientific data, and implement immediate corrective action, if needed.

The future of commercial cannabis cultivation hinges on using science to control the growing environment in order to remain competitive and deliver a premium grade of product on a consistent basis. The company holds a competitive advantage through its ability to produce premium cannabis products at a significantly lower cost per gram than direct competitors and others in the cannabis industry.

Innovations within the sector that create efficiencies and successful brands will become highly valued. Green Hygienics and its forward-thinking management team are constantly studying the market dynamics of the cannabis industry in North America and abroad while actively pursuing possible expansion opportunities. The company is headquartered in Las Vegas, Nevada and establishing operations in San Diego, California, targeting the $5 billion California cannabis market.

Green Hygienics Holdings Inc. (GRYN), closed the day's trading session at $0.61, up 2.26%, on 43,626 volume with 20 trades. The average volume for the last 3 months is 28,583 and the stock's 52-week low/high is $0.061/$0.618.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com (OTCQB: CIIX), a premier provider of financial news and education for the Chinese-speaking community, recently revealed its new ‘opt’ brand, which features two lines — opt Hemp and opt2mist — and connects its domestic hemp-infused consumer products. To view the full article, visit: http://nnw.fm/Zhzl3. Also today, the company was highlighted on MoneyTV with Donald Baillargeon

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.46, up 6.98%, on 135,868 volume with 85 trades. The average volume for the last 3 months is 86,401 and the stock's 52-week low/high is $0.365/$1.25.

Recent News

chart

Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN)

The QualityStocks Daily Newsletter would like to spotlight Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN).

Production disruptions in Brazil and other market dynamics have contributed to surging iron ore prices (http://nnw.fm/of10L). According to the Commonwealth Bank, iron ore prices could be heading back to $100 a ton, a level that has not been reported since 2014. These market dynamics have created stimuli for iron ore miners to enhance their extraction and production efforts. Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) is already seeing 2019 as a pivotal year for the company’s development and for its primary project – the Shymanivske Iron Ore Mine.

Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) is a Canadian iron ore exploration and development company advancing to production its wholly owned Shymanivske Iron Ore Project, located in Krivyi Rih, Ukraine. Black Iron’s Shymanivske project is situated in the southern part of the historic KrivBass iron ore mining district, a highly developed iron ore mining region with well-established infrastructure and nearby skilled labor forces. Surrounded by seven producing iron ore mines, the Shymanivske project will produce an ultra-high-grade, 68-percent iron ore concentrate with few impurities at very low cost.

The Market

Iron ore concentrates are one of the essential raw materials used by the steel industry to either make sinter or highly valued pellets. Black Iron’s concentrate can be used in either application and is an ideal source to make pellets since it does not need to be ground finer and contains very few impurities. According to the CRU Group, an internationally recognized top global business intelligence provider and consultancy specializing in commodities, there is a growing global shortage of pellet feed resulting in a supply/demand gap of 133Mt against the current base of approximately 400Mt consumed by 2035. According to a recent report issued by Zion Market Research, the global iron ore pellets market was valued at around US$25.22 billion in 2017 and is expected to reach US$50.12 billion by 2024, growing at a compound annual growth rate (CAGR) of 8.1 percent between 2018 and 2024 (http://nnw.fm/2vaDR).

Countries around the world, most notably China (http://nnw.fm/Je8gs), have instituted regulatory changes to curb polluting emissions from steel mills through numerous methods, including encouraging a shift to higher grade iron feed products such as pellets as less coal needs to be burnt per ton of steel produced.

Shymanivske Project

Black Iron’s Shymanivske’s project, which is expected to produce ultra-high-grade 68 percent iron content pellet feed iron concentrate, is generating significant interest from steel mills and global commodity trading houses. Use of ultra-high-grade 68-percent iron content product in the production of steel is a value-added product to customers since it increases blast furnace productivity and reduces greenhouse gas emissions generated per ton of steel produced.

The project’s proximity to rail lines (1 mile), electrical power (20 miles), sea ports (140 to 260 miles) and a skilled workforce (6 miles) significantly reduces the up-front construction costs and allows for the mine to be built in a phased approach. The Shymanivske project has been ranked by the CRU Group in the lowest position of the business cost curve for pellet feed projects currently under development and as the second lowest in capital intensity (construction capital divided by annual production) within CRU Group’s extensive database (http://nnw.fm/3MXsT). This low-cost position makes the project economics very robust to any shocks in iron ore price while providing a very high return at current and forecast prices.

Black Iron continues to advance its project on several fronts including construction funding and off-take agreements (http://nnw.fm/tQ4g2). Discussions with Ukraine’s Ministry of Defense to transfer a parcel of land required by the company for location of its processing plant, waste rock and tailings are nearing finalization, as are discussions with the Kryviy Rih City Council to lease a portion of the surface rights currently under that body’s control. The recent engagement of Ivan Markovich as Black Iron’s Vice President of Government and Community Relations will assist the company in these endeavors given his extensive network of relationships with senior Ukraine government officials.

The Shymanivske project holds a mining allotment permit for a large iron ore deposit with a NI 43-101 compliant resource estimated to contain 646 Mt (million tons) Measured and Indicated mineral resources, consisting of 355 Mt Measured mineral resources grading 31.6% total iron and 18.8% magnetic iron, and Indicated mineral resources of 290 Mt grading 31.1% total iron and 17.9% magnetic iron, using a cut-off grade of 10% magnetic iron. Additionally, there are 188 Mt of Inferred mineral resources grading 30.1% total iron and 18.4% magnetic iron.

Full mineral resource details and project economics can be found in the NI 43-101 compliant technical report entitled “Preliminary Economic Assessment of the Re-scoped Shymanivske Iron Ore Deposit” effective November 21, 2017, under the Company’s profile on SEDAR at?www.sedar.com.

Management

Black Iron’s management and board of directors is stacked with experts well-versed in successfully building and operating iron ore projects. CEO Matt Simpson, P.Eng. is the former general manager of Mining for Rio Tinto’s Iron Core Company of Canada and worked for Hatch designing global metallurgical refineries. He is also a Qualified Person as defined by NI 43-101. Chairman Bruce Humphrey is the former COO of GoldCorp and former chairman of Consolidated Thompson Iron Ore mines which was sold to Cliff’s resources for US$4.9 billion.

Les Kwasik, COO, has over 40 years of hands-on experience building and operating mines globally with companies such as INCO (VALE) and Xstrata (Glencore). Paul Bozoki, CFO, is the former CFO of CD Capital Partners, operating in the Ukraine. Bill Hart, senior vice president of corporate development, has over 30 years of experience selling iron ore while working for Rio Tinto, Cliffs Natural Resources and most recently Roy Hill Holdings Ltd. Ivan Markovich was recently engaged in the capacity of Black Iron’s vice president of Government and Community Relations to leverage his extensive network of relationships with senior Ukraine government officials.

Black Iron Inc. (BKIRF), closed the day's trading session at $0.046, up 4.78%, on 45,910 volume with 9 trades. The average volume for the last 3 months is 40,775 and the stock's 52-week low/high is $0.0285/$0.0939.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

CannabisNewsAudio announces the Audio Press Release (APR) titled “Smart Investment Leads to Big Opportunities in Growing Cannabis Market,” featuring SinglePoint Inc. (OTCQB: SING). To hear the CannabisNewsAudio version, visit: http://cnw.fm/dZbK7. To read the full editorial, visit: http://nnw.fm/ib8GI. Also today, it was announced that Jacksam/Convectium Corporation, in which SING has an 8.6% ownership, is to present at the 31st Annual ROTH Investor Conference. Additionally, the company was featured on this week’s episode of MoneyTV with Donald Baillargeon. To view the full interview, visit: http://nnw.fm/17uCb. To view the full press release, visit: http://nnw.fm/wv3Gu and http://nnw.fm/mbO0B.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.019, up 4.40%, on 2,846,573 volume with 105 trades. The average volume for the last 3 months is 5,926,494 and the stock's 52-week low/high is $0.0106/$0.068.

Recent News

chart

Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4)

The QualityStocks Daily Newsletter would like to spotlight Redfund Capital Corp. (PNNRF).

Established as a global merchant bank, Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (Frankfurt: O3X4) aims to provide debt and equity funding to companies in the mid and later stages of development. This business strategy is a core component of Redfund as it seeks to establish the foundations of a loan portfolio that generates revenue with monthly interest income and that also grows value for shareholders (http://nnw.fm/Rh2OJ).

Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4) is a merchant bank focused on providing debt and equity funding in the mid to late stages of a target company’s development and for technologies that are developed and validated by revenues. Redfund’s current focus is on medical cannabis, hemp and cannabidiol (CBD) related and healthcare-related companies.

As the first medical cannabis incubator and accelerator financing medical cannabis, CBD and hemp companies through a debt facility, Redfund is effectively bridging finance gaps and helping revenue-producing medical cannabis-related companies grow and build their valuations without prematurely diluting their equity.

The central components of the company’s business strategy are:

  • Establishing the foundation of a loan portfolio that generates revenues through monthly interest income from loans to cover all general and administrative expenses related to day-to-day operations.
  • Growing shareholder value by converting all or part of loans and warrants into equity in portfolio clients as clients build their valuations by entering the public markets or becoming the high-priced targets of larger entities.

Redfund was designed by bankers and entrepreneurs possessing years of experience in business, consulting, capital markets, corporate finance and healthcare services. The company is actively looking beyond borders and creating global companies that have strong fundamentals and are ready to expand.

Redfund’s investments are deployed to companies that have demonstrated success in their business but need a capital bridge in order to expand. Redfund’s team of professionals vet every project and analyzes each prospective client’s financials and business plans. Once a project is approved, Redfund’s legal team carefully scrutinizes the collateral used to securitize the individual loans.

The strategy employed by Redfund includes:

  • Diversifying investments in Canada and other countries
  • Building an international footprint with established national leaders
  • Funding new drug delivery systems and helping nutraceuticals become mainstream drugs
  • Introducing companies to Canada as a viable option for public listings
  • Becoming a premier go-to lender for established companies

The company’s revenue sources include:

  • Interest-bearing debt instruments with asset-backed collateral to securitize loans
  • Equity kicker of warrants coverage on original loan
  • Conversion ability of loan in its entirety
  • Advisory fees from contracts for consulting on growth strategies
  • Right of first refusal on future financing in each company funded

Redfund Capital Corp. (PNNRF), closed the day's trading session at $0.165205, even for the day, on 8,499 volume. The average volume for the last 3 months is 416 and the stock's 52-week low/high is $0.10/$0.505.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) has just made it easier for investors to trade its securities. The company recently announced that its shares are now Depository Trust Company (DTC) eligible (http://nnw.fm/gJu6q).

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $4.476, off by 0.97%, on 59,115 volume with 175 trades. The stock's 52-week low/high is $2.81/$6.01.

Recent News

chart

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Automotive technology innovator Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX) this morning announced the pricing of an underwritten public offering of 4,000,000 American Depositary Shares (“ADSs”), each at a price to the public of $1.50 per ADS, with expected gross proceeds of approximately $6,000,000 to the company. To view the full press release, visit: http://nnw.fm/M0zYm.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $1.64, off by 16.33%, on 534,978 volume with 1,052 trades. The average volume for the last 3 months is 40,088 and the stock's 52-week low/high is $1.47/$4.43.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) was featured today in the 420 with CNW by CannabisNewsWire. You would expect that with more than 17 years of existence in Canada, medical cannabis should have already led to policy changes in various aspects of life in the country. However, if the claims of injured workers are anything to go by, workers’ compensation guidelines have been slow in changing to accommodate this form of treatment. Now matters are beginning to shift as the discussion below shows.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.20, off by 3.88%, on 160,749 volume with 169 trades. The average volume for the last 3 months is 173,175 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Innovative hemp and cannabis corporation Marijuana Company of America (OTCQB: MCOA) recently received a U.S. patent for its hempSMART Brain that places it in a decidedly stronger position in the U.S. hemp-based product market, forecast to reach nearly $2 billion in three years. To view the full article, visit: http://nnw.fm/e6DTe. Also today, MCOA was featured in the 420 with CNW by CannabisNewsWire.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.011, off by 3.51%, on 10,312,387 volume with 311 trades. The average volume for the last 3 months is 11,212,971 and the stock's 52-week low/high is $0.01025/$0.0498.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.4851, up 11.95%, on 22,921 volume with 19 trades. The average volume for the last 3 months is 14,633 and the stock's 52-week low/high is $0.009/$1.139.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.